(Q33712682)

24885703

28 July 2017

title

Clinical baseline factors predict response to natalizumab: their usefulness in patient selection (English)

1 reference

28 July 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Maria Pia Sormani

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Antonio Uccelli

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Gianluigi Mancardi

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Ilaria Gandoglia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Claudio Solaro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Giuseppe Ribizzi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Tiziana Tassinari

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Matteo Pizzorno

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Sergio Parodi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Giovanna Baldassarre

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Maria Teresa Rilla

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Simonetta Venturi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Elisabetta Capello

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

12 May 2014

1 reference

28 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

6 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045962

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045962

Three years of experience: the Italian registry and safety data update.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045962

New perspectives in the natural history of multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045962

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045962

The cohort of the multiple sclerosis center of Cagliari.

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

The pharmacovigilance program on natalizumab in Italy: 2 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Clinical predictors of an optimal response to natalizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2377-14-103

Natalizumab: a country-based surveillance program

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4045962

Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification

30 October 2018

1 reference

12 December 2020

Regression to the mean in multiple sclerosis

1 reference

12 December 2020

Predicting beta-interferon failure in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2377-14-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

6 June 2020

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2377-14-103

9 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

24885703

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24885703%20AND%20SRC:MED&resulttype=core&format=json